Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial

FDA accepts NDA for dual Srk and Abl inhibitor bosutinib in previously-treated Philadelphia chromosome-positive CML on a positive news day for Pfizer. Meanwhile, review in front-line CML is pending in Europe.